Top

Published in:

01-01-2021 | Pleural Mesothelioma | Review and Perspectives

Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas

Authors: Lynnette Fernandez-Cuesta, Lise Mangiante, Nicolas Alcala, Matthieu Foll

Published in: Virchows Archiv | Issue 1/2021

Abstract

The diagnosis and classification of malignant pleural mesothelioma (MPM) is extremely challenging; obtaining an accurate histopathological diagnosis of the different types and subtypes requires expert assessment and suitable biopsies that are not always available, which can leave doctors uncertain about the patient’s diagnosis, sometimes resulting in a delay in the start of treatment. In this review, we discuss recent major advances in the molecular characterisation of MPM and their implications for histological classification. We detail what is known of the molecular landscape of MPM at the genomic, transcriptomic, and epigenomic levels, describe the similarities and dissimilarities of the multiple molecular classifications that have been proposed, and provide an overview of the current state of knowledge regarding inter- and intra-tumour heterogeneity. We also highlight the current gaps in knowledge and how addressing them would benefit classification, as well as the patients in general.

Baumann F, Ambrosi JP, Carbone M (2013) Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol 14:576–578. https://doi.org/10.1016/s1470-2045(13)70257-2CrossRefPubMed

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI (2019) Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69:402–429. https://doi.org/10.3322/caac.21572CrossRefPubMedPubMedCentral

Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S (2016) Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 11:1246–1262. https://doi.org/10.1016/j.jtho.2016.04.028CrossRefPubMedPubMedCentral

Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE (2018) Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 36:2863–2871. https://doi.org/10.1200/jco.2018.78.5204CrossRefPubMedPubMedCentral

Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M (2018) A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol 36:3485–3494. https://doi.org/10.1200/jco.2018.79.0352

Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE (2019) Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A 116:9008–9013. https://doi.org/10.1073/pnas.1821510116CrossRefPubMedPubMedCentral

Goodman JE, Nascarella MA, Valberg PA (2009) Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 20:1237–1254. https://doi.org/10.1007/s10552-009-9357-4CrossRefPubMed

Vivero M, Bueno R, Chirieac LR (2018) Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol 31:122–131. https://doi.org/10.1038/modpathol.2017.108CrossRefPubMed

Attanoos RL, Pugh MR (2018) The diagnosis of pleural tumors other than mesothelioma. Arch Pathol Lab Med 142:902–913. https://doi.org/10.5858/arpa.2017-0537-RACrossRefPubMed

10.

Baumann F, Carbone M (2016) Environmental risk of mesothelioma in the United States: an emerging concern-epidemiological issues. J Toxicol Environ Health B Crit Rev 19:231–249. https://doi.org/10.1080/10937404.2016.1195322CrossRefPubMed

11.

Price B, Ware A (2009) Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39:576–588. https://doi.org/10.1080/10408440903044928CrossRefPubMed

12.

Xu A, Wu LJ, Santella RM, Hei TK (1999) Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells. Cancer Res 59:5922–5926PubMed

13.

Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M (2013) Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol 183:1654–1666. https://doi.org/10.1016/j.ajpath.2013.07.029CrossRefPubMedPubMedCentral

14.

Carbone M, Yang H (2012) Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18:598–604. https://doi.org/10.1158/1078-0432.ccr-11-2259CrossRefPubMed

15.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260. https://doi.org/10.1097/jto.0000000000000630CrossRefPubMed

16.

Nicholson AG, Sauter JL, Nowak A, Kindler H, Gill R, Remy-Jardin M, Armato S, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiolt P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F (2019) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 15:29–49. https://doi.org/10.1016/j.jtho.2019.08.2506

17.

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407–416. https://doi.org/10.1038/ng.3520CrossRefPubMed

18.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Salle F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 8:1548–1565. https://doi.org/10.1158/2159-8290.cd-18-0804CrossRefPubMedPubMedCentral

19.

Oey H, Daniels M, Relan V, Chee TM, Davidson MR, Yang IA, Ellis JJ, Fong KM, Krause L, Bowman RV (2019) Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis 40:724–734. https://doi.org/10.1093/carcin/bgz066CrossRefPubMed

20.

Quetel L, Meiller C, Assié JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC, Hofman V, Gibault L, Badoual C, Pintilie E, Hofman P, Monnet I, Scherpereel A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D (2020) Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol 14:1207–1223. https://doi.org/10.1002/1878-0261.12651CrossRefPubMedPubMedCentral

21.

de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20:1323–1334. https://doi.org/10.1158/1078-0432.ccr-13-2429CrossRefPubMed

22.

López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66:2970–2979. https://doi.org/10.1158/0008-5472.can-05-3907CrossRefPubMed

23.

Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H (2008) Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 453:627–635. https://doi.org/10.1007/s00428-008-0689-3CrossRefPubMed

24.

Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D (2019) Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun 10:1333. https://doi.org/10.1038/s41467-019-09307-6CrossRefPubMedPubMedCentral

25.

Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L (2019) Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine 48:191–202. https://doi.org/10.1016/j.ebiom.2019.09.003CrossRefPubMedPubMedCentral

26.

Oehl K, Vrugt B, Opitz I, Meerang M (2018) Heterogeneity in malignant pleural mesothelioma. Int J Mol Sci 19:1603. https://doi.org/10.3390/ijms19061603

27.

Chirieac LR, Hung YP, Foo WC, Hofer MD, VanderLaan PA, Richards WG, Sugarbaker DJ, Bueno R (2019) Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer 125:4164–4171. https://doi.org/10.1002/cncr.32416CrossRefPubMed

28.

Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT (2017) Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology 6:e1278330. https://doi.org/10.1080/2162402x.2016.1278330CrossRefPubMedPubMedCentral

29.

Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G (2019) Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol 14:276–287. https://doi.org/10.1016/j.jtho.2018.10.001CrossRefPubMed

30.

Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J (2020) Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. Clin Cancer Res 26:5477–5486. https://doi.org/10.1158/1078-0432.ccr-20-1767CrossRefPubMedPubMedCentral

31.

Felley-Bosco E (2018) Special issue on mechanisms of mesothelioma heterogeneity: highlights and open questions. Int J Mol Sci 19:3560. https://doi.org/10.3390/ijms19113560

32.

Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM (2020) Malignant pleural mesothelioma: genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers (Basel) 12:1186. https://doi.org/10.3390/cancers12051186

33.

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, Girard N, Elemento O, Nicholson AG, Blay JY, Galateau-Sallé F, Wainrib G, Clozel T (2019) Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med 25:1519–1525. https://doi.org/10.1038/s41591-019-0583-3CrossRefPubMed

34.

Fu Y, Jung AW, Torne RV, Gonzalez S, Vöhringer H, Shmatko A, Yates LR, Jimenez-Linan M, Moore L, Gerstung M (2020) Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat Can 1:800–810. https://doi.org/10.1038/s43018-020-0085-8CrossRef

35.

Kather JN, Heij LR, Grabsch HI, Loeffler C, Echle A, Muti HS, Krause J, Niehues JM, Sommer KAJ, Bankhead P, Kooreman LFS, Schulte JJ, Cipriani NA, Buelow RD, Boor P, Ortiz-Brüchle N, Hanby AM, Speirs V, Kochanny S, Patnaik A, Srisuwananukorn A, Brenner H, Hoffmeister M, van den Brandt PA, Jäger D, Trautwein C, Pearson AT, Luedde T (2020) Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Can 1:789–799. https://doi.org/10.1038/s43018-020-0087-6CrossRef

36.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–1414. https://doi.org/10.1016/s0140-6736(15)01238-6CrossRefPubMed

37.

Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon J-C, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM (2020) ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 55:1900953. https://doi.org/10.1183/13993003.00953-2019CrossRefPubMed

38.

Scherpereel A, Wallyn F, Albelda SM, Munck C (2018) Novel therapies for malignant pleural mesothelioma. Lancet Oncol 19:e161–e172. https://doi.org/10.1016/s1470-2045(18)30100-1CrossRefPubMed

39.

Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18:623–630. https://doi.org/10.1016/s1470-2045(17)30169-9CrossRefPubMed

40.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239–253. https://doi.org/10.1016/s1470-2045(18)30765-4CrossRefPubMed

41.

Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P (2019) Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 7:260–270. https://doi.org/10.1016/s2213-2600(18)30420-xCrossRefPubMed

42.

Baas P, Scherpereel A, Nowak AK (2020) First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743WCLC 2020 Virtual Presidential Symposium on August 8, 2020, Online

43.

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res 25:5485–5492. https://doi.org/10.1158/1078-0432.ccr-19-0103CrossRefPubMed

44.

Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N (2020) Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. J Thorac Oncol 15:1037–1053. https://doi.org/10.1016/j.jtho.2020.01.025CrossRefPubMed

Title: Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas
Authors: Lynnette Fernandez-Cuesta
Lise Mangiante
Nicolas Alcala
Matthieu Foll
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Pleural Mesothelioma
Pleural Mesothelioma
Published in: Virchows Archiv / Issue 1/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-020-02980-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond

Common and rare carcinomas of the thymus

Pleural mesothelioma classification update

The pulmonary pathology of COVID-19

Vaping-related lung injury

Challenges in lung and thoracic pathology